Sherwyn Schwartz, M.D.
Paul Michael Ramirez, Ph.D.
Dr. Paul Michael Ramirez is a specialist in psychometric assessments for CNS research trials. He is currently the President of CNS Ratings, LLC and is Professor of Neuroscience/Neuropsychology, Psychopathology and Psychopharmacology within the Clinical Psychology Doctoral Program at Long Island University in New York City
Dr. Ramirez has made over 200 professional presentations, and over the past 20 years, has provided rater training for assessment scales across CNS indications as well as for the assessment of cognitive disorders throughout North America, South America, Central America, Asia, Eastern and Western Europe, Scandinavia and South Africa. He was also formally co-founder and CEO of the Prophase Training Group (now doing business as ProPhase). Dr. Ramirez has published numerous papers on schizophrenia and other major mental disorders and has been Principal Investigator on grants from the National Institute of Health (NIH), National Cancer Institute (NCI), The National Institute of General Medical Sciences (NIGMS) and pharmaceutical industry sponsors.
Dr. Ramirez is also listed as a contributing author of the Positive and Negative Syndrome Scale (PANSS) and is co-author of the Informant Questionnaire for the PANSS (IQ-PANSS) and co-author of the official MHS Japanese translation of the PANSS.
Dr. Ramirez completed his doctoral degree in Psychology at The City College of The City University of New York with a specialization in Clinical Neuropsychology and a sub specialization in Clinical Psychopathology. He later completed a Postdoctoral Program in Psychopharmacology at Fairleigh Dickerson University. Dr. Ramirez also earned an M.Phil. in Psychology (Conc.: Neuropsychology) from the Graduate School & University Center, City University of New York.
Louis Kirby, M.D.
Tom Haskins, Ph.D.
J. Thomas Haskins, Ph.D. is a pharmaceutical professional with over 25 years of research (discovery and clinical Phases I-IV) and management experience (both US and international assignments) in the neurosciences. Tom has experience in the global clinical development of new products in the therapeutic indications of generalized anxiety disorder, panic disorder, major depressive disorder, schizophrenia (injectable antipsychotics), neuropathic pain, hypnotics, stroke and Alzheimer’s disease. Presently Tom is an independent consultant to the pharmaceutical industry, advising clients on clinical development plan content, product differentiation strategies, and protocol design. Earlier he was leader of new product identification and development effort for products originating both internally and externally. Previously, Tom lead matrix style teams for multiple pipeline assets and was responsible for development of these molecules from the bench through the end of Phase 2a (GMP, GLP, GCP, regulatory interactions, biomarker development, etc.). This extensive experience in managing and optimizing research teams, implementing productive research and product differentiation strategies, interfacing with marketing and executive management and highly effective alliance management has resulted in his wide recognition for integrity, diligence, dependability and expertise. Tom is also widely recognized by key opinion leaders and academic institutions for effective and productive sponsor/investigator relationships.
Steven Leventer, Ph.D.
John Carlos Diaz
John Carlos Diaz is the President and Owner of GeoSera Consulting, a Minority Business Enterprise that specializes in Clinical Research by executing Clinical Development Plans across multiple clinical trials. Prior to starting GeoSera, John Carlos worked in Clinical Research for 10 years as a Clinical Operations Leader tasked with delivering endpoints within timelines and budgets. John Carlos has had various Clinical Operations roles with increasing levels of responsibility. Beginning at Merck in 2008, in Clinical Pharmacology through Cephalon/Teva managing phase I – IV, global, adult/pediatric clinical research from 2010 to 2015 and finally as the Clinical Operations leader for pipeline of Braeburn Pharmaceuticals. Prior to entering the Clinical Research Role, John Carlos was a Sr. Scientist at GSK within Drug Metabolism and Pharmacokinetics. After graduating from New York University in 2002 with a Bachelors in Biochemistry, John Carlos expanded his education base by obtaining professional certificates in Finance and Accounting from the Wharton School at University of Pennsylvania, Clinical Research at Villanova University while finishing a Master’s degree in clinical research at George Washington University.